Fulcrum Therapeutics
FULC
81 hedge funds and large institutions have $250M invested in Fulcrum Therapeutics in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 26 reducing their positions, and 21 closing their positions.
150% more call options, than puts
Call options by funds: $3.1M | Put options by funds: $1.24M
37% more capital invested
Capital invested by funds: $183M → $250M (+$67.2M)
1.33% more ownership
Funds ownership: 89.89% → 91.22% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 88 → 81 (-7)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
35% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
+$6.26M |
| 2 |
CAC
Cowen and Company
New York
|
+$5.21M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$4.51M |
| 4 |
Millennium Management
New York
|
+$1.88M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.27M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.97M |
| 3 |
Renaissance Technologies
New York
|
-$1.28M |
| 4 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$1.13M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.09M |
FULC Hedge Fund Activity: Q3 2023 in Review
81 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q3 2023, worth a combined $250M — up 37% from $183M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of FULC and 15 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 17 added.
The largest buyer was Jefferies Financial Group, opening a new position worth an estimated $6.26M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $6.27M sold.
- 81 institutional investors held Fulcrum Therapeutics (FULC) as of Q3 2023, down from 88 in Q2 2023.
- Funds reported $250M of Fulcrum Therapeutics stock for Q3 2023, up 37% quarter-over-quarter.
- 15 funds opened new Fulcrum Therapeutics positions in Q3 2023 and 21 closed out, a net change of -6 holders.
- The largest Fulcrum Therapeutics buyer in Q3 2023 was Jefferies Financial Group, an estimated $6.26M added.
- The largest Fulcrum Therapeutics seller in Q3 2023 was Point72 Asset Management, an estimated $6.27M sold.
Based on aggregated 13F filings for Q3 2023.